RIPK1-IN-19
RIPK1-IN-19 is a selective RIPK1 inhibitor (IC50=15 nM) . RIPK1-IN-19 does not show obvious activity against RIPK2, RIPK3, and RIPK4. RIPK1-IN-19 displays potent protective activity in TNFα-induced systemic inflammatory response syndrome (SIRS) model and Imiquimod (IMQ) -induced psoriasis model. RIPK1-IN-19 can be used in research on inflammation and immune system diseases[1].
Product Specifications
CAS Number
2763831-43-0
UNSPSC
12352005
Target
RIP kinase
Type
Reference compound
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/ripk1-in-19.html
Purity
98.87
Solubility
10 mM in DMSO
Smiles
C[C@@H](C1=CC=CC(F)=C1)NC(C2=CN(C3=C2C=C(C=C3)C4=CC5=NC(NC(C6CC6)=O)=NN5C=C4)C)=O
Molecular Formula
C28H25FN6O2
Molecular Weight
496.54
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
RIPK1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Collagen IV (COL4A2) (NM_001846) Human Over-expression Lysate
1-Phenyl-1,2-propanediol (Mixture of Diastereomers)
Recombinant SARS-CoV-2 Spike RBD (N501Y) (His Tag)
Recombinant SARS-CoV-2 Spike RBD (N501Y) (His Tag)
